EN DE
Watch Lineage Cell Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lineage Cell Therapeutics Inc (LCTX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Lineage Cell Therapeutics Inc stock $0.75, price $1.04, that is 27.9% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LC Lineage Cell Therapeutics Inc logo Thin data Nov 10, 2026

Lineage Cell Therapeutics Inc

LCTX · US
Expensive, weak quality

Our calculation puts a fair price 28% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +79.9 %/yr in USD)
Revenue last quarter 61% below a year ago.
Fair value $0.7500 · Overvalued
Quality 30/100
Negative free cash flow
Trails peers (1/9)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Lineage Cell Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.79 $0.3861 Fair Value $0.7500 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.3861 – $2.79 · fair‑value band $0.5600 – $0.9300 · the $1.04 price screens above the $0.7500 fair value. As of Nov 10, 2026.

Follow Lineage Cell Therapeutics in your weekly email

Every Wednesday you see whether Lineage Cell Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.

Show moreShow less

The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.

It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.

In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology.

The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates.

The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Stock analysis

Lineage Cell Therapeutics Inc (LCTX) currently trades at $1.04, while our estimate is $0.7500, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.5600 (bear) to $0.9300 (bull), the price of $1.04 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lineage Cell Therapeutics Inc reported revenue of $14.6M in FY2025 versus $3.9M in FY2021, a compound +39.0%/yr. Reported net income was −$63.5M in FY2025.

Key figures

Market cap $272M Micro · P/S ratio 19.0 · EPS (TTM) $−0.1900 · Return on equity −60.1% · Return on assets (EBIT) −21.8% (5-year average) · Operating margin −835% · Revenue (TTM) $13.1M · Revenue growth (YoY) −61.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −28%, LCTX screens richer than that median.

Fair Value

Bear $0.5600 Fair Value $0.7500 Bull $0.9300
Price $1.04 · Downside -27.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 10
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyBrian M CulleyPresident and CEO, Director15,000 shares at $1.63$24,450Mar 12, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+53.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+79.9%
Start year 2020 (pandemic). Over 10 years: +19.1% a year
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,421.3% (2020) → −149.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LCTX screens overvalued: fair value 28% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Lineage Cell Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −27.9% · Below median
Profitability
Return on assets −56.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −61.3% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.10× · Priciest 25%
P/S (12 months) 20.79× · Priciest 25%
PEG 10.64× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs LCTX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs LCTX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs LCTX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs LCTX
argenx SE ARGX $971.55 $908.40 −7% vs LCTX
CSL Limited CSL A$201.68 A$181.40 −10% vs LCTX
Moderna, Inc MRNA $250.83 $158.70 −37% vs LCTX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs LCTX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs LCTX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs LCTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lineage Cell Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lineage Cell Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/LCTX

Frequently asked questions

Is Lineage Cell Therapeutics Inc (LCTX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.7500 versus a price of $1.04, about 28% lower (overvalued).
What is the fair value of LCTX?
Our estimate for Lineage Cell Therapeutics Inc is $0.7500 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.04.
What is the quality score of LCTX?
Lineage Cell Therapeutics Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lineage Cell Therapeutics Inc (LCTX)?
Our calculated price target is the estimate of $0.7500 (as of Nov 10, 2026). Cautious scenario $0.5600, optimistic scenario $0.9300. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Lineage Cell Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $0.7500, about 28% lower versus a price of $1.04 (overvalued). Cautious scenario $0.5600, optimistic scenario $0.9300. The calculation is refreshed regularly with new filings.
What is the revenue of Lineage Cell Therapeutics Inc (LCTX)?
Lineage Cell Therapeutics Inc reported trailing-twelve-month revenue of about $13.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Lineage Cell Therapeutics Inc (LCTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lineage Cell Therapeutics Inc it is $0.7500 per share (as of Nov 10, 2026), against a price of $1.04.
Is Lineage Cell Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, LCTX trades above its calculated fair value: price $1.04, fair value $0.7500, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LCTX?
No. The price is what the market pays today ($1.04); the fair value is what the company's own numbers justify ($0.7500). For Lineage Cell Therapeutics Inc the two are $0.2900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lineage Cell Therapeutics Inc worth?
The market values Lineage Cell Therapeutics Inc at about $272M (market capitalisation, as of Nov 10, 2026). Per share that is $1.04; our models calculate a fair value of $0.7500 per share.
What do the bullish and bearish scenarios say about LCTX?
Our models span a range for Lineage Cell Therapeutics Inc: cautious scenario $0.5600, base $0.7500, optimistic $0.9300 per share (as of Nov 10, 2026, price $1.04). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of LCTX?
The PEG ratio of Lineage Cell Therapeutics Inc is 10.64 (P/E divided by earnings growth, as of Nov 10, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Lineage Cell Therapeutics Inc (LCTX)?
Balance-sheet figures for Lineage Cell Therapeutics Inc (as of Nov 10, 2026): return on equity −60.1%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is LCTX from its 52-week high?
Lineage Cell Therapeutics Inc trades at $1.04, about 47% below its 52-week high of $1.96 and 15% above the low of $0.9042 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7500 is for.
Which stocks are comparable to Lineage Cell Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lineage Cell Therapeutics Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $1.04, calculated fair value $0.7500 (−28%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Lineage Cell Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lineage Cell Therapeutics Inc (LCTX)?
The closing price on Nov 10, 2026 was $1.04. Our estimate is $0.7500, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lineage Cell Therapeutics Inc right now?
The price sits above even our optimistic bull case ($0.9300). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Lineage Cell Therapeutics Inc

How large is the market capitalisation of Lineage Cell Therapeutics Inc (LCTX)?
The market capitalisation of Lineage Cell Therapeutics Inc is $272M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lineage Cell Therapeutics Inc (LCTX)?
The price-to-sales ratio of Lineage Cell Therapeutics Inc is 19.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lineage Cell Therapeutics Inc (LCTX)?
Earnings per share at Lineage Cell Therapeutics Inc are $−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lineage Cell Therapeutics Inc (LCTX)?
The return on equity (ROE) of Lineage Cell Therapeutics Inc is −60.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lineage Cell Therapeutics Inc (LCTX)?
On an EBIT basis the return on assets of Lineage Cell Therapeutics Inc is −21.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lineage Cell Therapeutics Inc (LCTX)?
The operating margin of Lineage Cell Therapeutics Inc is −835% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lineage Cell Therapeutics Inc (LCTX)?
Revenue at Lineage Cell Therapeutics Inc is growing −61.3% versus a year earlier (3y avg −0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lineage Cell Therapeutics Inc (LCTX) generate?
The free cash flow of Lineage Cell Therapeutics Inc is −$19.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lineage Cell Therapeutics Inc (LCTX) hold?
Lineage Cell Therapeutics Inc holds more cash than debt, $38.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lineage Cell Therapeutics Inc in the live analysis

One click puts Lineage Cell Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.